<DOC>
	<DOCNO>NCT02039089</DOCNO>
	<brief_summary>This study single-center , multiple-dose , randomize , double-blind , placebo-controlled , parallel-group study healthy male female subject . The study consist 2 part : Part A ( 3 cohort healthy Japanese subject dose even ) Part B ( one cohort healthy white subject dose even ) . The cohort conduct sequentially . Part A start first 2.5-mg dose cohort , follow 10-mg dose cohort 25-mg dose cohort . Part B conduct parallel 10-mg cohort Part A , possibility overlap .</brief_summary>
	<brief_title>A Two-Part Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E2006 Healthy Japanese White Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Subjects meet follow criterion include study : 1 . Nonsmoking , male female subject age great equal 20 year less equal 55 year old time inform consent . 2 . Japanese subject must bear Japan Japanese parent Japanese grandparent , must live 5 year outside Japan , must change life style habit , include diet , live outside Japan . 3. Who report habitual time bed great 7 hour , lightsout 21:00 24:00 hour lightson 06:00 09:00 hour . 4. Who report typical sleep latency less equal 30 minute . 5 . With typical total sleep time great equal 420 minute . 6 . Body mass index ( BMI ) great equal 18 less equal 28 kg/m2 Screening . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week dose . 2 . Any subject know history malaria travel country know malarial risk ( ie , country designate 'high ' 'moderate ' risk accord list available http : //www.cdc.gov/malaria ) within last year . 3 . Evidence disease may influence outcome study within 4 week dose ( eg , psychiatric disorder , disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism ) . 4 . Any history abdominal surgery may affect PK profile E2006 ( eg , hepatectomy , nephrotomy , digestive organ resection ) . 5 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , ECG assessment , laboratory test result require medical treatment . 6 . A QTcF interval great 450 m demonstrate repeat ECGs ( repeat initial ECG indicate QT great 450 m ) Screening Baseline . 7 . A history family history congenital QT prolongation history risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT Syndrome ) , use concomitant medication prolong QT/QTc interval . 8 . Any suicidal ideation intent without plan Baseline within 6 month Baseline ( ie , answer `` Yes '' question 4 5 Suicidal Ideation Section CSSRS ) . 9 . Any lifetime suicidal behavior ( per Suicidal Behavior Section CSSRS ) . 10 . Known history clinically significant drug allergy screening . 11 . Known history food allergy presently ( Screening Baseline ) experience significant seasonal perennial allergy . 12 . Active viral hepatitis ( A , B C ) demonstrate positive serology Screening . Subjects HIV infection confirm verbally . 13 . History drug alcohol dependency abuse within 2 year Screening , positive urine drug test breath ( urine ) alcohol test Screening Baseline . 14 . Habitually consume 400 mg caffeine per day . Caffeine consumption must discontinue least 24 hour Baseline checkin . 15 . Intake nutritional supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , brussel sprout , mustard ] , charbroiled meat ) within 1 week dosing . 16 . Intake herbal preparation contain St. John 's Wort within 4 week dose . 17 . Use prescription drug within 4 week dose . 18 . Intake overthecounter medication within 2 week dose . 19 . Currently enrol another clinical study use investigational drug device within 30 day precede initial dose study drug . 20 . Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week dosing . 21 . Engagement strenuous exercise within 2 week Screening checkin ( eg , marathon running , weight lift ) . 22 . Diagnosis sleep disorder ( eg , insomnia , obstructive sleep apnea , restless leg syndrome , Periodic Limb movement Sleep , narcolepsy , circadian rhythm disorder ) . 23 . Performed shift work within 2 week Screening . 24 . Had take airline flight across 3 time zone 7 day Screening .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>